Nyxoah S.A. (NYXH)

Market Cap	300.38M
Revenue (ttm)	4.83M
Net Income (ttm)	-48.01M
Shares Out	28.66M
EPS (ttm)	-1.65
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	29,662
Open	10.68
Previous Close	10.92
Day's Range	10.04 - 11.24
52-Week Range	4.00 - 20.00
Beta	0.48
Analysts	Strong Buy
Price Target	18.40 (+75.57%)
Earnings Date	May 14, 2024

About NYXH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Jul 2, 2021
• Employees: 146
• Stock Exchange: NASDAQ
• Ticker Symbol: NYXH

Financial Performance

In 2023, Nyxoah's revenue was 4.35 million, an increase of 40.99% compared to the previous year's 3.08 million. Losses were -43.21 million, 38.4% more than in 2022.

Financial numbers in EUR

Analyst Forecast

According to 6 analysts, the average rating for NYXH stock is "Strong Buy." The 12-month stock price forecast is $18.4, which is an increase of 75.57% from the latest price.

Price Target

$18.4

(75.57% upside)

Analyst Consensus: Strong Buy